XOMA Disclosed It Had Received An $8.1M Milestone Payment From Viracta Therapeutics, Inc., Related To Day One Biopharmaceuticals' Recent Sale Of Its Priority Review Voucher (prv) For $108MTo An Undisclosed Buyer
Portfolio Pulse from Benzinga Newsdesk
XOMA received an $8.1M milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals' sale of its Priority Review Voucher (PRV) for $108M to an undisclosed buyer.
June 12, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
XOMA received an $8.1M milestone payment from Viracta Therapeutics, which is linked to Day One Biopharmaceuticals' sale of its Priority Review Voucher for $108M.
The $8.1M milestone payment is a significant revenue boost for XOMA, likely to positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100